Although parathyroid hormone agents are typically used in clinical trials, they have limitations in clinical use owing to different medicinal effects followed by changes in the concentration and lower efficacy compared to bisphosphonates, the typical osteoporosis drugs [28]. This evidence concerns the gene PTH and osteoporosis.